Real-World Studies
Neurosurgical Resection in De Novo NSCLC Brain Metastases: Outcomes and Prognostic Drivers
Wang et alJournal of Clinical Medicine
A retrospective real-world cohort study evaluated 248 consecutive patients undergoing neurosurgical resection for non-small cell lung cancer brain metastases (NSCLC-BM) to determine outcomes in patients with concurrent or early-detected pulmonary and intracranial lesions (de novo disease, defined as detection within 1 month of diagnostic work-up). Overall, 113 patients (45.6%) presented with de novo brain metastases. Compared to patients with metachronous lesions, those with de novo presentation were significantly more likely to present with symptomatic and multifocal intracranial disease.
Among 73 patients with de novo presentation who had evaluable survival data, neurosurgical resection yielded a median postoperative overall survival (OS) of 57.0 months (95% CI, 22.9–not reached). Comparative multivariable Cox regression analyses demonstrated that postoperative OS and intracranial progression-free survival (iPFS) did not differ significantly between de novo and metachronous cohorts, confirming that de novo presentation is not an independent adverse prognostic indicator for survival. Furthermore, Firth logistic regression identified driver-mutation positivity and lower intracranial tumor burden as key factors associated with durable long-term postoperative survival within the de novo population. These findings support neurosurgical resection as a feasible and effective component of multidisciplinary management for carefully selected patients with de novo NSCLC-BM.
Key Takeaways
- In surgically treated de novo non-small cell lung cancer brain metastases (n=73 evaluable), median postoperative overall survival was 57.0 months (95% CI, 22.9–not reached), showing no significant difference in overall survival or intracranial progression-free survival compared to metachronous metastases.
- Driver-positive mutation status and lower intracranial tumor burden were significantly associated with durable postoperative survival in the de novo brain metastasis subgroup.
Read the original sourceJournal of Clinical Medicine
